IC
NTLA icon

IEQ Capital’s Intellia Therapeutics NTLA Stock Holding History

IEQ Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Sell
49,375
-3,723
-7% -$52.1K ﹤0.01% 1186
2026
Q1 		$681K Buy
+53,098
New +$676K ﹤0.01% 1175
2025
Q4 		– Sell
-21,447
Closed -$370K – 1953
2025
Q3 		$370K Buy
+21,447
New +$264K ﹤0.01% 1428
2025
Q2 		– Sell
-11,473
Closed -$81.6K – 1937
2025
Q1 		$81.6K Buy
+11,473
New +$116K ﹤0.01% 1508

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

IEQ Capital's NTLA Position: Q2 2026 in Review

IEQ Capital reduced its Intellia Therapeutics (NTLA) stake by 7% in Q2 2026, selling an estimated $52.1K and leaving 49,375 shares worth $835K. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

IEQ Capital first reported a position in NTLA in Q1 2025 and has held it in 4 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • IEQ Capital held 49,375 shares of Intellia Therapeutics worth $835K as of Q2 2026.
  • IEQ Capital sold 3,723 Intellia Therapeutics shares in Q2 2026, an estimated $52.1K.
  • Intellia Therapeutics made up ﹤0.01% of IEQ Capital's portfolio in Q2 2026, its #1186 holding.
  • IEQ Capital first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.